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Abstract
The global rise in the resistance of pathogens to conventional antibiotics has created an intensive
search for alternative materials with antimicrobial properties. This study is performed with an
intention to investigate the combined effects of poly(L-glutamic acid)-capped silver nanoparticles
(AgNpPGA) and ascorbic acid (AscH) encapsulated within freeze-dried poly(lactide-co-glycolide)
(PLGA) nanospheres to obtain a nanomaterial with simultaneous osteoinductive, antioxidative,
and prolonged antimicrobial properties. The influence of PLGA/AgNpPGA/AscH particles on (i)
viability and super-oxide production of human umbilical vein endothelial cells in vitro, (ii)
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morphology and expression of osteogenic markers in osteoblastic MC3T3-E1 cells in vitro, and
(iii) antimicrobial activity against a Gram-positive bacterium, methicillin-resistant Staphylococcus
aureus, and a Gram-negative bacterium, Escherichia coli, was investigated. PLGA/AgNpPGA/
AscH nanoparticles showed a superior and extended antibacterial activity against both types of
bacteria. The nanoparticles appeared to be capable of delivering ascorbate to the cells, which was
evidenced by the significant decrease in the level of superoxides in human umbilical vein
endothelial cells and which could have a therapeutic potential in preventing oxidative stress.
PLGA/AgNpPGA/AscH nanoparticles had a positive effect on MC3T3-E1 osteoblastic cells in
vitro, promoting: (i) an intimate contact with the cells and preservation of their healthy
morphologies; (ii) unreduced cell viability; and (iii) multiple-fold upregulation of two osteogenic
markers: osteocalcin and type I procollagen. It is concluded that PLGA/AgNpPGA/AscH
nanospheres present a promising new material for the treatment of infections and use in wound
dressings and other prophylactic applications.
Keywords
nanotechnology; PLGA; silver nanoparticles; osteoinductivity; antibacterial material; antioxidative
effects
INTRODUCTION
Medical devices are significant risk factors for nosocomial infections, a.k.a. hospital-
acquired infections, not present nor incubating at admission.1−3 These infections are
widespread and are important contributors to hospital morbidity. The most common
hospital-acquired infections include those of surgical wounds, bloodstream, lower
respiratory tract, skin, and urinary tract.4 Many different microorganisms may cause them.
For example, the Gram-positive bacterium Staphylococcus aureus causes a variety of lung,
bone, heart, and bloodstream infections. Gram-negative bacteria, such as Enterobacteriaceae
(e.g., Escherichia coli, Klebsiella, etc.), may colonize sites due to weakened host defenses
(catheter insertion, cannula insertion, etc.) and elicit a variety of disease states consequential
to infection.1−5 Both of these types of infections may be highly resistant to traditional
antibiotic therapies. In fact, the global rise in the resistance of pathogens to conventional
antibiotics has created an intensive search for alternative materials with antimicrobial
properties. Metallic nanoparticles, e.g., silver, gold, and platinum, count as some of the most
promising of these alternative inorganic materials with antibacterial and antiviral
properties.6−8 They have been used in an effort to reduce the scope of infection, though in
many cases with rather unsatisfactory clinical outcomes.9
Due to their large surface-to-weight ratio, nanoparticles exhibit higher solubility,
physicochemical reactivity, and antimicrobial activity when compared to conventional
preparations. However, metallic nanoparticles might cause diverse side effects, primarily
related to the induced production of reactive oxygen species (ROS), known for their ability
to damage various cellular organelles and disrupt the normal cell and tissue physiology.8 A
disequilibrium between the formation of reactive oxygen species and the defensive,
antioxidant molecular species has been involved in the pathogenesis of a variety of ailments,
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such as respiratory diseases, cancer, diabetes, and cardiovascular and neurodegenerative
diseases.8,10 Synergism of two or more drug combinations increasingly attracts attention as
a promising approach to overcome the adverse side effects that limit the clinical
applicability of many potential drugs.11 Therefore, it is of vital significance to devise a co-
delivery system that would enable loading of two or more drugs at the same time and
transportation to one or multiple target sites. During the last few decades, polymers
comprising lactic and glycolic acids and their copolymers have attracted interest as
prospective drug delivery carriers in pharmaceutics and tissue engineering.12,13 Poly-
(lactide-co-glycolide) (PLGA) is made from two monomers: lactide (diester of lactic acid)
and glycolide (diester of glycolic acid), both of which are biocompatible, biodegradable, and
nontoxic, in surgical and in drug delivery systems alike.14 Optimization of the properties of
particles, in respect to their most favored interfaces with cells, is of the utmost importance
for the biomedical community, being at the same time a major challenge in the field of
biomaterials. Common methods to produce PLGA micro- and nanospheres include the
emulsification−solvent−evaporation technique (modification of this method is dual or
multiple emulsion technique), emulsification−solvent−extraction, and phase separation.15 In
comparison with these methods, the physicochemical solvent/nonsolvent method with freeze
drying is a relatively simple, reproducible, rapid, and easily scalable technique. Recently, we
have synthesised PLGA microspheres loaded with polyglutamic acid (PGA) capped silver
nanoparticles (AgNpPGA)16 using the physicochemical solvent/nonsolvent technique.17 We
have demonstrated in vitro that the toxicity of bare silver nanoparticles (AgNps) can be
reduced: (i) by capping these nanoparticles with an organic layer, i.e., by coating with
poly(L-glutamic acid) (AgNpPGAs) and (ii) by their encapsulation (incorporation) within a
PLGA polymeric matrix (PLGA/AgNpPGAs). Also, we have shown that these PLGA/
AgNpPGA particles can achieve bacterial inhibition levels higher than AgNps or
AgNpPGAs.17
The purpose of this study has been to combine the freeze-drying method with the
physicochemical solvent/nonsolvent approach in the preparation of multifunctional PLGA
nano-spheres encapsulating AgNpPGA and the common antioxidant, ascorbic acid (vitamin
C, AscH). The next aim was to assess its potential not only as an antibacterial material but
also as one with pronounced antioxidative properties. In addition, we examined the
osteoinductive potential of PLGA/AgNpPGA/AscH nano-spheres in vitro.
EXPERIMENTAL SECTION
Freeze-Drying Preparation and Characterization of PLGA/AgNpPGA/AscH Nanospheres
Details about chemicals used for the synthesis of PLGA/AgNpPGA/AscH nanospheres are
provided within the Supporting Information (SI).
PLGA/AgNpPGA/AscH nanospheres were produced using a combination of the
physicochemical solvent/nonsolvent method and freeze drying. First off all AgNpPGAs
were prepared in our laboratory as described in previous reports16,18 (a procedure of
obtaining AgNpPGAs is described in the SI). Then, the solution containing AgNpPGAs was
added to an aqueous solution of ascorbic acid (0.1 wt %), continuously being homogenized
at 300 rpm during 20 minutes, with the resulting solution becoming grayish green. The
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volume ratio between the solution containing silver nanoparticles and the solution
containing ascorbic acid was 1:3. Additionally, such an obtained mixture of AgNpPGAs and
ascorbic acid was encapsulated within the PLGA matrix (Figure 1). AgNpPGA/ascorbic
acid was added dropwise to PLGA solution in acetone (120 mg in 20 mL). Afterwards 22
mL of ethanol as nonsolvent was added, and at that instant, after the diffusion of solvent into
nonsolvent, PLGA with immobilized AgNpPGA and ascorbic acid precipitates, and the
solution becomes whitish. This was followed by addition (stabilization) of the obtained
suspension PLGA/AgNpPGA/ AscH dropwise into 45 mL of PVP (0.05 wt %). The
reactions were conducted at room temperature and ambient pressure. The content of
AgNpPGA/AscH was adjusted to produce particles with PLGA/ AgNpPGA/AscH ratio of
80/5/15 wt %. Previously we have shown that the optimal PLGA/AscH ratio for retaining
sphericity of the particles is 85/15 per weight.19,20 The resulting emulsion was stirred to
allow the organic solvent to evaporate and subsequently poured into a Petri dish and placed
into a freezer for overnight incubation. Freeze-drying, a.k.a., lyophilization, was utilized at
−57 °C and the pressure of 0.3 mbar. The main drying was performed at −57 °C for 8.5 h,
and the final drying was done for 30 min at −30 °C using Freeze Dryer Martin Christ Alpha
1-2/ LD plus. The encapsulation efficiency (EE %) was found to be more than 90%.
An integrated study of the nanosphere composition and structure was carried out by
combining different techniques, i.e., by XRD analysis, field emission scanning electron
microscopy (FE-SEM), and dynamic light scattering (DLS). The more details regarding
characterization of the samples are provided within the SI.
The effect of different amounts of samples, blank PLGA particles, or PLGA/AgNpPGA/
AscH nanoparticles, on the basal level of intra-cellular superoxide, was measured using a
fluorescent sensor for superoxide, hydroethidine (Invitrogen). Human umbilical vein cells
(HUVECs) were used, and intracellular superoxide formation was detected with
hydroethidine (HE). Cells were incubated with 5 uM HE for 10 min and further processed as
previously described21 and as explained within the SI.
The influence of PLGA/AgNpPGA/AscH nanoparticles on the HUVECs growth and
viability was determined by the mitochondrial-dependent reduction of MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) to formazan, as formerly reported22
and described in the SI.
The protocol for the determination of the effect of samples on MC3T3-E1 osteoblastic cells
in vitro was performed as described previously23,24 with modifications and as provided
within the SI.
The antibacterial activity of released AgNpPGA/ascorbic acid from PLGA/AgNpPGA/AscH
nanospheres was evaluated against Gram-positive bacterium, methicillin-resistant
Staphylococcus aureus (MRSA; ATCC 43300), and Gram-negative bacterium Escherichia
coli (ATCC 25922). The antibacterial activity was evaluated by the broth microdilution
method, and MICs were determined following the guidelines of a CLSI.25The procedure for
the evaluation of the antibacterial activity is also given in the SI.
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RESULTS AND DISCUSSION
XRD Analysis
XRD diffraction was used for the phase composition analysis of PLGA/AgNpPGA/AscH
particles. No crystalline peaks of the poly(lactide-co-glycolide) have been observed,
suggesting its amorphous nature (Figure 2a). The characteristic reflections of ascorbic acid,
(002) at 2Θ = 28.0, (−302) at 2Θ = 29.9, (200) at 2Θ =10.4, (010) at 2Θ = 19.8 (according to
ICDD 04-0308),26 appeared after its encapsulation in PLGA nanospheres (Figure 2(b)). This
indicates that AscH was successfully encapsulated by PLGA particles. The XRD analysis
led to confirmation of the silver phase, with characteristic strong Bragg reflections
corresponding to (111), (200), (220), and (311) planes of fcc silver (JCPDS No.4-0783).27,28
It indicates the silver nanoparticles were incorporated too within the PLGA particles.
Morphology Studies
PGA, a hydrophilic anionic polyelectrolyte, was employed as capping agent to prevent
agglomeration of the AgNps as well as to make them be more biocompatible. As-prepared
AgNpPGAs were stable in sols over prolonged periods of time, with no sign of phase
separation (Figure 3a). Figure 3b shows representative FESEM images of as-prepared PGA-
capped Ag nanoparticles. From these images it can be seen that AgNpPGAs had nearly
spherical shapes. The synthesized AgNpPGAs were uniform, with a narrow particle size
distribution and mean size of about 5 nm. Larger AgNpPGAs with sizes of about 15−30 nm
were clusters of the smaller Ag nanoparticles. Measurements of the particle size distribution
based on DLS showed that 10% of particles were 5 nm in diameter; 50% of particles had
diameters of less than 21 nm, while 90% of particles were of diameters below 45 nm (Figure
3c).
Without liophilization, PLGA/AgNpPGA/AscH particles prepared by the physicochemical
solvent/nonsolvent method and by drying at room temperature had a similarly narrow size
distribution but were micrometer-sized (Figure 4). Figure 4 shows spherical particles with a
smooth surface.
Freeze-dried PLGA/AgNpPGA/AscH particles were analyzed by FESEM and by DLS to
study their morphology and to quantify the particle size. PLGA/AgNpPGA/AscH particles
were uniform and spherical and had a smooth and regular surface (Figure 5A). A size
distribution curve for PLGA/AgNpPGA/ AscH particles is presented in Figure 3B. The
results showed that 10% of the particles were 86 nm in diameter; 50% of particles had
diameters of less than 142 nm, while 90% of particles were of diameters below 397 nm
(Figure 5B). The physicochemical solvent/nonsolvent method is based on the solvent
(acetone) diffusion into nonsolvent (ethanol), which results in a fast precipitation and phase
separation of the PLGA polymer. After the solvent evaporation and partial freezing in the
freezer, the process of freeze drying has been utilized. During the lyophilization, a very
important parameter, the product's temperature, cannot be directly controlled. However,
parameters such as ambient and condensation temperatures, chamber pressure, duration of
lyophilization, the type of cryoprotectant, etc., can be controlled, and these parameters were
adjusted to obtain uniformly spherical particles on the nanometre scale. PVP, used in our
Stevanović et al. Page 5
ACS Appl Mater Interfaces. Author manuscript; available in PMC 2014 June 13.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
experiment as a stabilizer for PLGA particles, also served as cryoprotectant during
lyophilization of these particles. Also, the optimal duration of lyophilization turned out to be
9 h. PLGA/AgNpPGA/AscH particles generated by the physico-chemical solvent/
nonsolvent method and freeze drying had smaller sizes than particles dried at room
temperature (Figure 4 and Figure 5). The submicrometer size of the nanoparticles is
associated with countless advantages over their microparticulate counterparts. In general,
they have a higher intracellular uptake efficiency compared to microparticles. For example,
100 nm sized nanoparticles exhibited 2.5-fold greater uptake when compared to 1 μm sized
particles and 6 times higher uptake when compared to 10 μm sized microparticles.29
The zeta potential of the PLGA/AgNpPGA/AscH particles remained unchanged, with zeta
potential value of −30.2 ±10.5 mV in the pH range 4.3−4.5, before and after freeze-drying.
Detection of Superoxide and MTT Assay
In our previous work and prior to those experiments of detection of superoxide, the
influence of the samples AgNp, AgNpPGAs, and PLGA/ AgNpPGAs17 and additionally of
PLGA/AgNpPGA/AscH nanoparticles on the production of the reactive oxygen species
within cells was determined by dichloro-dihydro-fluorescein diacetate (DCFH-DA) assay,30
with minor modifications.31 The protocol was performed as described previously.31,17 The
data from ROS study of prepared PLGA/AgNpPGAs and PLGA/ AgNpPGA/AscH
nanoparticles were provided in the Supporting Information (SI) as Figure S1. A study on
oxidative stress induced in the human hepatoma cell line (Hep G2 cells) confirmed PLGA/
AgNpPGAs does not cause generation of intracellular reactive oxygen species (Figure S1b,
SI). Moreover, there was reduction of DCF fluorescence in comparison to the controls, for
the PLGA with encapsulated AgNpPGAs at 0.1% (Figure S1b, SI). One possible
explanation is, as Arora et al. demonstrated in vitro in rat fibroblasts and liver cells, that
lower doses of silver nanoparticles can elicit a protective effect against the oxidative stress
via a decrease in lipid peroxidation and, at the same time, an increase in glutathione
transferase and superoxide dismutase production, the two species that play a critical role in
decomposing ROS in organisms.32 Another possibility is that PLGA has a protective role
against oxidative stress-induced cell death. According to Reddy and collaborators, PLGA
nano-particles protected in vitro culture of human fetal neurons against oxidative stress
challenged with hydrogen peroxide.33 However, we have obtained even more interesting
results in the case of PLGA/AgNpPGA/AscH nanoparticles which at concentrations of 0.01,
0.1, and 1% (v/v) caused a significant decrease in DCF fluorescence, which was after 5 h
exposure 2-fold lower than that in control cells (Figure S1a, SI). This indicates that PLGA/
AgNpPGA/AcsH nanoparticles either act as scavengers of intracellular reactive oxygen
species and/or reduce their formation.
To further verify and confirm these results, we have tested the ability of blank PLGA and
PLGA/AgNpPGA/AscH nano-particles to scavenge a superoxide anion radical.
The superoxide anion radical (O2•−) is a one-electron-reduced byproduct of respiration that
is considered to be a constituent of reactive oxygen species (ROS).34 Normally produced by
mitochondria, superoxide is detoxified by the class of enzymes called superoxide dismutases
(SOD).34 However, with aging and in different pathologies, such as inflammation-based
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diseases, the amount of produced O2•− increases or/and the activity of the SOD enzyme
decreases, leading to oxidative stress and tissue damage.35 Ascorbate is known to scavenge
ROS and prevent oxidative stress.36 We have thus tested the ability of blank PLGA and
PLGA/AgNpPGA/AscH nanoparticles to scavenge super-oxide that is produced by the
mitochondrial electron transport chain.
First, the effect of PLGA/AgNpPGA/AscH nanoparticles on cell growth was tested by MTT
assay. No significant changes on cell proliferation were observed in the first 24 h of
incubation with 1, 2.5, and 5 mg/mL of PLGA/AgNpPGA/AscH nanoparticles (data not
shown), suggesting that neither the carrier nor the coated particles is toxic for the cells in the
used concentration range.
Next, hydroethidine (HE) loaded HUVECs were incubated for 45 min with the same
concentration range of PLGA/ AgNpPGA/AscH nanoparticles and 5 mg/mL of blank
PLGA. The characteristic fluorescence of 2-hydroxyethidium, which is the product of the
reaction of HE with superoxide, was then observed by fluorescence microscopy (Figure 6A)
and semi-quantified (Figure 6B) using ImageJ (NIH) software. As shown in Figure 6,
superoxide was detected in untreated HUVECs as a consequence of the normal respiration
process. Treatment with the highest dose of blank PLGA did not induce any considerable
change in the amount of intracellular superoxide. However, treatment with only 1 mg/mL of
PLGA/AgNpPGA/AscH nanoparticles halved the intracellular level of superoxide. The
doses of 2.5 and 5 mg/mL almost completely abolished the intracellularly produced
superoxide. These data demonstrate that PLGA/AgNpPGA/AscH nanoparticles appeared to
be capable of efficiently delivering ascorbate to the cells, which could have an immense
therapeutic potential in preventing oxidative stress. The cellular uptake of vitamin C is
somewhat limited by the fact that cells more efficiently take dehydroascorbate than vitamin
C, which in turn has to be reduced back to ascorbate.32 Our data suggest that
pharmacologically efficient amounts of vitamin C could be easily achieved by the use of
PLGA/AgNpPGA/AscH nanoparticles.
Effect of PLGA/AgNpPGA/AscH Particles on MC3T3-E1 Osteoblastic Cells in Vitro
Results of the investigation of the effect of PLGA/AgNpPGA/AscH nanoparticles on
MC3T3-E1 osteoblastic cells in culture are shown in Figure 7. Figure 7a,b displays the
confocal optical images of fluorescently counter-stained osteoblastic cells of the control
sample (Figure 7a) and following incubation with the ascorbic-acid-containing particles
prepared within this study (Figure 7b). The cells appear to be spread well on the glass
surface, and no patches of dying or morphologically unhealthy cells were observed,
suggesting a viable response of the cells to the material. The light microscopy image shown
in Figure 7c demonstrates the direct contact established between the nanoparticles and the
cells, suggesting furthermore the cells’ attraction to the particles, a good indicator of their
osteoconductivity. Finally, as shown in Figure 7d, the gene expression of two major
osteogenic markers, osteocalcin and type I procollagen, was markedly more upregulated
compared to the control: 3-fold for osteocalcin and more than 4-fold for type I procollagen.
One possible explanation is that ascorbic acid is required for the differentiation of MC3T3-
E1 fibroblasts to osteoblasts. Ascorbic acid was, for example, shown to drastically increase
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the expression of alkaline phosphatase and osteocalcin.37 With the additional
supplementation of this compound to the cells, their osteoblastic markers become further
expressed. Ascorbic acid is also involved in the formation of collagen,38 which may explain
the boosted expression of the gene encoding for its main precursor, type I procollagen,
following the treatment with the particles loaded with ascorbic acid.
Biomaterials for bone engineering applications are usually divided into three categories:
osteoconductive, osteoinductive, and osteogenic.39 While osteoconductive materials are
conducive to new bone growth on their surface, the osteoinductive ones are able to induce
recruitment, differentiation, and proliferation of bone cells, and the osteogenic ones are,
according to the standard definition of, internally enriched with osteoprogenitor cells,
undifferentiated mesenchymal stem cells, or cells already differentiated into the osteoblastic
lineage. The osteoinductive nature of PLGA/AgNpPGA/AscH nanoparticles is evidenced
hereby by their ability to upregulate the expression of osteocalcin and type I procollagen in
osteoblastic MC3T3-E1 cells.
Antibacterial Activity
β-Lactams represent the cornerstones of conventional anti-infective therapies.40 Their
central downside comes from the fact that the clinical application of β-lactams can result in
the increased prevalence and virulence of the bacterial strains targeted by the therapy. The
exploration of venues that would lead to alternative antibacterial therapies consequently
presents one of the central challenges posed before modern medicine.41,42
To assess the antibacterial activity of released AgNpPGA, samples were tested against
Gram-positive Staphylococcus aureus (MRSA) and Gram-negative Escherichia coli (Figure
8 and Figure S2 in the enclosed SI). We evaluated the release media from an early time
point in the experiment, day 2, as well as later time points, days 28, 59, and 82 (Figure 8),
and the MICs of the tested compounds were determined. The data demonstrate that the
media containing released silver exhibit strong antibacterial activity against S. aureus as
well as E. coli, with the media collected at 28 and 59 day time points being even more
antibacterially active in the case of S. aureus than media which contained initially released
silver. In the case of E. coli, the MIC remained almost the same up to 59 days followed by
an increase at the 82 day time point. A similar increase in the MIC also occurred in the case
of S. aureus at day 82. The different behavior and MICs between the two bacterial strains up
to 59 days can be explained by assuming that at the given concentration of AgNps the
growth inhibition depends on the initial number of cells.43 On the other side, the possible
explanation of such similar behavior at 82 day might be that silver nanoparticles at the later
time points are more agglomerated, thus creating clusters which pose lesser antibacterial
activity. This is in line with the previously reported findings.40 One of them is that the small
size of the particles facilitates their penetration across the cell membrane and endows them
with the ability to affect the intracellular processes. Additionally, tremendous antibacterial
properties exhibited by silver nanoparticles are owing to their large surface, which allows
for a maximum contact with the local environment,44 and positive surface charge, which
makes their penetration of the negatively charged cell membrane even more facile. It has
been known that silver nanoparticles are capable of penetrating the bacterial cell wall and
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imposing irretrievable damage on it and ultimately causing the death of the organism.45 In
addition, ascorbic acid was found to be effective in treating wound infection by interfering
with the colony formation of micro-organisms.46,47 Also, lactic acid, one of the products of
the PLGA degradation, is widely employed for controlling microbial growth which is
associated with the pH lowering effect.48 In one form or another, silver and its compounds
have long been used as antimicrobial agents. Understanding the antimicrobial mechanism of
nanoparticle formulations is important for the sake of creating an optimal synergy with
biomolecules. To gain a better insight into the mechanism of action of silver nanoparticles as
bactericidal as well as antifungal or antiviral agents, further examination of the membrane-
bound and intracellular nano-particles45will be needed.
CONCLUSION
In this study, a simple, combined freeze-drying method and physicochemical solvent/
nonsolvent approach to preparation of multifunctional PLGA nanospheres encapsulating
AgNpPGAs and ascorbic acid is demonstrated. Freeze-dried PLGA/ AgNpPGA/AscH
particles were uniform, spherical, and with the mean diameter of 142 nm. PLGA/
AgNpPGA/AscH nanoparticles appeared to be capable of efficiently delivering ascorbate to
the cells, which could have a tremendous therapeutic potential in preventing oxidative stress.
The given particles also had a positive effect on MC3T3-E1 osteoblastic cells in vitro. They
promoted an intimate contact with osteoblastic cells and preserved their healthy
morphologies, without reducing the cell viability. PLGA/AgNpPGA/AscH nanoparticles
showed multiple-fold upregulation of two osteogenic markers: osteocalcin and type I
procollagen. In addition, PLGA/AgNpPGA/AscH nanospheres prepared in this study
showed superior and extended antibacterial activity against Gram-positive methicillin-
resistant Staphylococcus aureus and Gram-negative Escherichia coli, the main causative
agents of orthopedic infections.
From the perspective of materials and device development, PLGA/AgNpPGA/AscH
particles exhibited strong bactericidal, antioxidative, and osteoinductive properties, making
them a promising candidate for application in the clinic, especially in orthopedic surgery.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Scheme that illustrates the multifunctional PLGA particle with encapsulated ascorbic acid
and PGA-capped silver nanoparticles.
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Figure 2.
XRD diffraction patterns of (a) PLGA, (b) PLGA/AscH, and (c) PLGA/AgNpPGA/AscH.
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Figure 3.
(A) Digital photo showing the yellow-green solution containing silver nanoparticles. (B)
Representative FESEM micrographs of silver nanoparticles coated by PGA (AgNpPGAs)
(bar 20 nm and 100 nm). (C) Particle size distribution of AgNpPGAs.
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Figure 4.
Representative FESEM (A, bar = 1 μm) and TEM (B) images of PLGA/AgNpPGA/AscH
particles dried at room temperature and prepared using identical parameters as for freeze-
dried formulation. The micrographs are given for comparison purposes. In the TEM
micrograph (inset on B) it may be seen that some particles are brighter and some darker, i.e.,
that AgNpPGAs and ascorbic acid have a different contrast.
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Figure 5.
(A) Representative FESEM images of freeze-dried PLGA/AgNpPGA/AscH particles (bar 1
μm) and (B) particle size distribution of PLGA/ AgNpPGA/AscH particles.
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Figure 6.
Detection of superoxide in HUVECs subjected to PLGA/AgNpPGA/AscH nanoparticles.
(A) Representative fluorescent microscopy images of the HUVECs preloaded with
hydroethidine, a superoxide sensitive fluorescent sensor, and then treated with either 5
mg/mL of PLGA or 1, 2.5, and 5 mg/mL of PLGA/AgNpPGA/AscH nanoparticles for 45
min. (B) Intensity of fluorescence determined from the experiment shown in (A). n =
50−100 cells; *p < 0.001 compared to the control, # p < 0.001 compared to the effect of 1
mg/mL of PLGA/AgNpPGA/AscH nanoparticles.
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Figure 7.
Effect of PLGA/AgNpPGA/AscH samples on MC3T3-E1 osteoblastic cells in vitro. (a, b)
Single plane confocal optical images of fluorescently counterstained osteoblastic MC3T3-E1
cells (red) after 7 days of incubation in differentiation medium: (a) control; (b) PLGA/
AgNpPGA/AscH. (c) Optical micrographs showing the interface between the osteoblastic
MC3T3-E1 cells and conglomerates of PLGA/AgNpPGA/AscH particles. Magnifications:
60× (a, b); 20× (c). (d) The effect of PLGA/AgNpPGA/AscH particles on the mRNA
expression of osteocalcin and type I procollagen in osteoblastic MC3T3-E1 cells. mRNA
expression was quantified by quantitative RT-polymerase chain reaction relative to the
housekeeping gene, β-actin. Data normalized to expression of β-actin are presented as
arithmetic means with error bars representing standard deviation. Both genes were
significantly (p < 0.05) upregulated with respect to the control group.
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Figure 8.
Antibacterial activity of PGA-capped silver nanoparticles released from freeze-dried PLGA/
AgNpPGA/AscH. (a) Schematic of the experiment. (b,c) Minimal inhibitory concentrations
of AgNpPGAs determined using a broth microdilution assay as a function of time, against E.
coli (b) and MRSA (c).
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